Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zlatal 25mg/1ml solution for injection pre-filled syringes
0801030P0BEACFG
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 48 |
|
Azathioprine 25mg/5ml oral suspension
0802010G0AACICI
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 46 |
|
Dailiport 1mg modified-release capsules
0802020T0BKABAN
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 43 |
|
Jayempi 10mg/ml oral suspension
0802010G0BIAACP
|
Jayempi | Azathioprine | Malignant Disease and Immunosuppression | 36 |
|
Methotrexate 12.5mg/0.5ml inj pre-filled syringes
0801030P0AAFJFJ
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 36 |
|
Rapamune 2mg tablets
0802020U0BBAEAE
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 36 |
|
Zlatal 10mg/0.4ml solution for injection pre-filled syringes
0801030P0BEADFH
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 34 |
|
Tacrolimus 1mg modified-release capsules
0802020T0AAANAN
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 32 |
|
Tacrolimus 2.5mg/5ml oral liquid
0802020T0AAAGAG
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 32 |
|
Toremifene 60mg tablets
0803041U0AAAAAA
|
Toremifene citrate | Toremifene citrate | Malignant Disease and Immunosuppression | 29 |
|
Zlatal 7.5mg/0.3ml inj pre-filled syringes
0801030P0BEAEFI
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 28 |
|
Enzalutamide 40mg tablets
0803042U0AAABAB
|
Enzalutamide | Enzalutamide | Malignant Disease and Immunosuppression | 25 |
|
Octreotide 500micrograms/1ml solution for injection vials
0803043N0AAAMAM
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 24 |
|
Ciclosporin 100mg/ml oral solution sugar free
0802020G0AAAGAG
|
Ciclosporin (Systemic) | Ciclosporin | Malignant Disease and Immunosuppression | 23 |
|
Faslodex 250mg/5ml inj pre-filled syringes
0803041AABBAAAA
|
Faslodex | Fulvestrant | Malignant Disease and Immunosuppression | 23 |
|
Tacrolimus 1mg gran for susp sachets sugar free
0802020T0AAAWAW
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 23 |
|
Tacrolimus 5mg capsules
0802020T0AAAAAA
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 23 |
|
Zlatal 17.5mg/0.7ml inj pre-filled syringes
0801030P0BEAHFL
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 23 |
|
Ciclosporin 10mg capsules
0802020G0AAAHAH
|
Ciclosporin (Systemic) | Ciclosporin | Malignant Disease and Immunosuppression | 22 |
|
Ceptava 180mg gastro-resistant tablets
0802010N0BCAAAA
|
Ceptava | Mycophenolic sodium | Malignant Disease and Immunosuppression | 20 |
|
Octreotide 10mg inj vials
0803043N0AAAEAE
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Sandostatin 100micrograms/1ml inj ampoules
0803043N0BBABAB
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Cyclophosphamide 50mg tablets
0801010H0AAAFAF
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | 18 |
|
Mercaptopurine 25mg capsules
0801030L0AAALAL
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 18 |
|
Tacrolimus 750microgram capsules
0802020T0AABFBF
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 18 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.